Crescent Biopharma (NASDAQ: CBIO) insider transactions

In the twelve months to 10 November 2026, executives and directors of Crescent Biopharma reported 16 open-market sales of 84,882 shares ($1.5m) and 2 open-market purchases of 2,213,450 shares ($30.6m), by 9 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Crescent Biopharma shares reported on Form 4
Date	Insider	Role	Transaction	Shares	Price	Held after	Filing
18 September 2026	McNeill Jonathan	President and COO	Open-market sale, 10b5-1 plan	−3,839	$16.71	134,588	Form 4
18 September 2026	Brumm Joshua T	Chief Executive Officer	Open-market sale, 10b5-1 plan	−7,837	$16.71	271,765	Form 4
16 September 2026	McNeill Jonathan	President and COO	Open-market sale, 10b5-1 plan	−731	$17.90	138,427	Form 4
16 September 2026	Brumm Joshua T	Chief Executive Officer	Open-market sale, 10b5-1 plan	−1,610	$17.90	279,602	Form 4
16 September 2026	Bispham Barbara Harlin	See Remarks	Open-market sale, 10b5-1 plan	−620	$17.90	18,710	Form 4
16 September 2026	Scalzo Richard William	Chief Financial Officer	Open-market sale, 10b5-1 plan	−568	$17.90	19,730	Form 4
16 September 2026	Im Ellie Eunkyung	Chief Medical Officer	Open-market sale, 10b5-1 plan	−623	$17.90	21,446	Form 4
16 September 2026	Pinkas Jan	Chief Scientific Officer	Open-market sale, 10b5-1 plan	−658	$17.90	21,581	Form 4
16 September 2026	Lynch Ryan	See Remarks	Open-market sale, 10b5-1 plan	−240	$17.90	13,631	Form 4
16 July 2026	Fairmount Healthcare Fund II L.P.	Director	Open-market purchase	+853,450	$14.50	3,601,316	Form 4
22 June 2026	Brumm Joshua T	Chief Executive Officer	Open-market sale, 10b5-1 plan	−42,305	$17.99	281,212	Form 4
22 June 2026	McNeill Jonathan	President and COO	Open-market sale, 10b5-1 plan	−20,549	$17.99	139,158	Form 4
22 June 2026	Im Ellie Eunkyung	Chief Medical Officer	Open-market sale, 10b5-1 plan	−1,219	$17.99	22,069	Form 4
22 June 2026	Bispham Barbara Harlin	See Remarks	Open-market sale, 10b5-1 plan	−1,218	$17.99	19,330	Form 4
22 June 2026	Scalzo Richard William	Chief Financial Officer	Open-market sale, 10b5-1 plan	−1,112	$17.99	20,298	Form 4
22 June 2026	Pinkas Jan	Chief Scientific Officer	Open-market sale, 10b5-1 plan	−1,288	$17.99	22,239	Form 4
22 June 2026	Lynch Ryan	See Remarks	Open-market sale, 10b5-1 plan	−465	$17.99	13,871	Form 4
15 December 2025	Bispham Barbara Harlin	See Remarks	Grant or award	+12,422	—	12,422	Form 4
15 December 2025	Bispham Barbara Harlin	See Remarks	Grant or award	+6,000	—	18,422	Form 4
15 December 2025	Lynch Ryan	See Remarks	Grant or award	+8,378	—	8,378	Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Crescent Biopharma page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.